Citigroup’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.78M Sell
21,900
-500
-2% -$233K ﹤0.01% 1487
2025
Q4
$10.2M Sell
22,400
-3,900
-15% -$1.68M ﹤0.01% 1521
2025
Q3
$10.3M Hold
26,300
﹤0.01% 1471
2025
Q2
$11.7M Buy
26,300
+19,900
+311% +$9.17M 0.01% 1280
2025
Q1
$3.1M Sell
6,400
-48,400
-88% -$22.6M ﹤0.01% 2332
2024
Q4
$22.1M Buy
54,800
+11,300
+26% +$5.24M 0.01% 905
2024
Q3
$20.2M Buy
43,500
+25,100
+136% +$12.1M 0.01% 938
2024
Q2
$8.62M Hold
18,400
0.01% 1329
2024
Q1
$7.69M Sell
18,400
-63,000
-77% -$26.6M 0.01% 1425
2023
Q4
$33.1M Buy
81,400
+37,900
+87% +$14M 0.02% 622
2023
Q3
$15.1M Buy
43,500
+31,500
+263% +$11M 0.01% 910
2023
Q2
$4.22M Buy
+12,000
New +$4.04M ﹤0.01% 1608
2023
Q1
Sell
-4,900
Closed -$1.42M 5894
2022
Q4
$1.42M Sell
4,900
-25,300
-84% -$7.71M ﹤0.01% 2306
2022
Q3
$8.74M Sell
30,200
-36,800
-55% -$10.6M 0.01% 1208
2022
Q2
$18.9M Buy
67,000
+20,000
+43% +$5.35M 0.01% 823
2022
Q1
$12.3M Sell
47,000
-55,000
-54% -$13.1M 0.01% 1193
2021
Q4
$22.4M Buy
102,000
+33,000
+48% +$6.42M 0.01% 945
2021
Q3
$12.5M Sell
69,000
-95,000
-58% -$18.5M 0.01% 1278
2021
Q2
$33.1M Buy
164,000
+125,000
+321% +$26.1M 0.02% 725
2021
Q1
$8.38M Sell
39,000
-46,500
-54% -$10.2M 0.01% 1470
2020
Q4
$20.2M Buy
85,500
+32,500
+61% +$7.46M 0.01% 1024
2020
Q3
$14.4M Buy
53,000
+4,200
+9% +$1.16M 0.01% 1113
2020
Q2
$14.2M Buy
48,800
+700
+1% +$190K 0.01% 1070
2020
Q1
$11.4M Sell
48,100
-31,300
-39% -$7.18M 0.01% 1069
2019
Q4
$17.4M Sell
79,400
-21,700
-21% -$4.39M 0.01% 1065
2019
Q3
$17.1M Buy
101,100
+18,100
+22% +$3.2M 0.01% 1015
2019
Q2
$15.2M Sell
83,000
-26,300
-24% -$4.6M 0.01% 1098
2019
Q1
$20.1M Sell
109,300
-1,400
-1% -$259K 0.02% 825
2018
Q4
$18.3M Sell
110,700
-17,100
-13% -$2.96M 0.02% 882
2018
Q3
$24.6M Buy
127,800
+26,400
+26% +$4.7M 0.02% 716
2018
Q2
$17.2M Buy
101,400
+9,800
+11% +$1.52M 0.02% 897
2018
Q1
$14.9M Buy
91,600
+23,200
+34% +$3.79M 0.01% 977
2017
Q4
$10.3M Sell
68,400
-37,800
-36% -$5.6M 0.01% 1278
2017
Q3
$16.1M Buy
106,200
+48,500
+84% +$7.3M 0.01% 907
2017
Q2
$7.44M Buy
57,700
+28,600
+98% +$3.44M 0.01% 1384
2017
Q1
$3.18M Sell
29,100
-21,600
-43% -$1.9M ﹤0.01% 2035
2016
Q4
$3.73M Sell
50,700
-11,100
-18% -$903K ﹤0.01% 2176
2016
Q3
$5.39M Buy
61,800
+15,500
+33% +$1.46M 0.01% 1600
2016
Q2
$3.98M Sell
46,300
-4,200
-8% -$363K ﹤0.01% 1777
2016
Q1
$4.01M Sell
50,500
-3,500
-6% -$317K ﹤0.01% 1752
2015
Q4
$6.79M Buy
54,000
+24,600
+84% +$2.97M 0.01% 1434
2015
Q3
$3.06M Buy
29,400
+13,300
+83% +$1.71M ﹤0.01% 2092
2015
Q2
$1.99M Buy
16,100
+900
+6% +$113K ﹤0.01% 2519
2015
Q1
$1.79M Sell
15,200
-63,400
-81% -$7.6M ﹤0.01% 2574
2014
Q4
$9.34M Sell
78,600
-43,900
-36% -$4.94M 0.01% 1328
2014
Q3
$13.8M Sell
122,500
-194,000
-61% -$18.5M 0.01% 1053
2014
Q2
$30M Buy
316,500
+147,700
+88% +$10.4M 0.03% 561
2014
Q1
$11.9M Sell
168,800
-18,800
-10% -$1.49M 0.01% 1030
2013
Q4
$13.9M Buy
187,600
+53,800
+40% +$3.75M 0.01% 986
2013
Q3
$10.1M Sell
133,800
-14,800
-10% -$1.18M 0.01% 1148
2013
Q2
$11.9M Buy
+148,600
New +$10.9M 0.01% 968

Other funds holding VRTX

Citigroup's VRTX Position: Q1 2026 in Review

Citigroup increased its Vertex Pharmaceuticals (VRTX) stake by 26% in Q1 2026, buying an estimated $66.6M and bringing the position to 682,807 shares worth $305M. The position accounts for 0.13% of the portfolio, ranked #153.

Citigroup first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Citigroup held 682,807 shares of Vertex Pharmaceuticals worth $305M as of Q1 2026.
  • Citigroup bought 142,877 Vertex Pharmaceuticals shares in Q1 2026, an estimated $66.6M.
  • Vertex Pharmaceuticals made up 0.13% of Citigroup's portfolio in Q1 2026, its #153 holding.
  • Citigroup first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.